» Articles » PMID: 36124784

DrDimont: Explainable Drug Response Prediction from Differential Analysis of Multi-omics Networks

Overview
Journal Bioinformatics
Specialty Biology
Date 2022 Sep 20
PMID 36124784
Authors
Affiliations
Soon will be listed here.
Abstract

Motivation: While it has been well established that drugs affect and help patients differently, personalized drug response predictions remain challenging. Solutions based on single omics measurements have been proposed, and networks provide means to incorporate molecular interactions into reasoning. However, how to integrate the wealth of information contained in multiple omics layers still poses a complex problem.

Results: We present DrDimont, Drug response prediction from Differential analysis of multi-omics networks. It allows for comparative conclusions between two conditions and translates them into differential drug response predictions. DrDimont focuses on molecular interactions. It establishes condition-specific networks from correlation within an omics layer that are then reduced and combined into heterogeneous, multi-omics molecular networks. A novel semi-local, path-based integration step ensures integrative conclusions. Differential predictions are derived from comparing the condition-specific integrated networks. DrDimont's predictions are explainable, i.e. molecular differences that are the source of high differential drug scores can be retrieved. We predict differential drug response in breast cancer using transcriptomics, proteomics, phosphosite and metabolomics measurements and contrast estrogen receptor positive and receptor negative patients. DrDimont performs better than drug prediction based on differential protein expression or PageRank when evaluating it on ground truth data from cancer cell lines. We find proteomic and phosphosite layers to carry most information for distinguishing drug response.

Availability And Implementation: DrDimont is available on CRAN: https://cran.r-project.org/package=DrDimont.

Supplementary Information: Supplementary data are available at Bioinformatics online.

References
1.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

2.
Budczies J, Brockmoller S, Muller B, Barupal D, Richter-Ehrenstein C, Kleine-Tebbe A . Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics. 2013; 94:279-88. DOI: 10.1016/j.jprot.2013.10.002. View

3.
Ogris C, Hu Y, Arloth J, Muller N . Versatile knowledge guided network inference method for prioritizing key regulatory factors in multi-omics data. Sci Rep. 2021; 11(1):6806. PMC: 7990936. DOI: 10.1038/s41598-021-85544-4. View

4.
Ortmayr K, Dubuis S, Zampieri M . Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat Commun. 2019; 10(1):1841. PMC: 6478870. DOI: 10.1038/s41467-019-09695-9. View

5.
Geeleher P, Zhang Z, Wang F, Gruener R, Nath A, Morrison G . Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res. 2017; 27(10):1743-1751. PMC: 5630037. DOI: 10.1101/gr.221077.117. View